日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy of Inactivated Bivalent SARS-CoV-2 Vaccines Targeting Ancestral Strain (ERAGEM), Delta, and Omicron Variants

针对祖先毒株(ERAGEM)、Delta 和 Omicron 变异株的灭活二价 SARS-CoV-2 疫苗的有效性

Kaplan, Busra; Pavel, Shaikh Terkis Islam; Uygut, Muhammet Ali; Tunc, Merve; Eroksuz, Yesari; Celik, Ilhami; Eren, Esma Eryilmaz; Korukluoglu, Gulay; Kara, Ates; Ozdarendeli, Aykut; Yetiskin, Hazel

Vaccination with inactivated SARS-CoV-2 vaccine TURKOVAC induces durable humoral and cellular immune responses up to 8 months.

接种灭活 SARS-CoV-2 疫苗 TURKOVAC 可诱导长达 8 个月的持久体液和细胞免疫反应

Yılmaz Seçil, Eken Ahmet, Sezer Zafer, Bağcı Burcu Şen, Erdem Serife, Sarıkaya Medine Doğan, Kaplan Busra, Inal Ahmet, Bayram Adnan, Kalın Unuvar Gamze, Zararsız Gokmen, Yerlitas Serra İlayda, Cakir Nuri, Pavel Shaikh Terkis Islam, Uygut Muhammet Ali, Yetiskin Hazel, Kara Ates, Ozdarendeli Aykut

Long-Term Immunogenicity and Safety of a Homologous Third Dose Booster Vaccination with TURKOVAC: Phase 2 Clinical Study Findings with 32-Week Post-Booster Follow-Up

TURKOVAC同源第三剂加强免疫疫苗的长期免疫原性和安全性:2期临床研究结果及加强免疫后32周随访

Sezer, Zafer; Pavel, Shaikh Terkis Islam; Inal, Ahmet; Yetiskin, Hazel; Kaplan, Busra; Uygut, Muhammet Ali; Aslan, Ahmet Furkan; Bayram, Adnan; Mazicioglu, Mumtaz; Kalin Unuvar, Gamze; Yuce, Zeynep Ture; Aydin, Gunsu; Kaya, Refika Kamuran; Ates, Ihsan; Kara, Ates; Ozdarendeli, Aykut

Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials

灭活全病毒SARS-CoV-2疫苗TURKOVAC在健康成人中的安全性和免疫原性:随机、双盲、安慰剂对照的1期和2期试验的中期结果

Ozdarendeli, Aykut; Sezer, Zafer; Pavel, Shaikh Terkis Islam; Inal, Ahmet; Yetiskin, Hazel; Kaplan, Busra; Uygut, Muhammet Ali; Bayram, Adnan; Mazicioglu, Mumtaz; Unuvar, Gamze Kalin; Yuce, Zeynep Ture; Aydin, Gunsu; Aslan, Ahmet Furkan; Kaya, Refika Kamuran; Koc, Rabia Cakir; Ates, Ihsan; Kara, Ates